Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: Insights from the REVEAL REGISTRY®

Mayo Clinic Proceedings

Volumn 87, Issue 9, 2012, Pages 825-834

  Kitterman, Natalie ^a   Poms, Abby ^b   Miller, Dave P ^c   Lombardi, Sandra ^d   Farber, Harrison W ^e   Barst, Robyn J ^f  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ICON Late Phase and Outcomes Research   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN; PROSTANOID; TEZOSENTAN; TREPROSTINIL;

ADULT; AGE; ARTICLE; BLOODSTREAM INFECTION; DISEASE REGISTRY; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; INFECTION RISK; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT INFORMATION; PULMONARY HYPERTENSION; RISK ASSESSMENT; RISK FACTOR;

EID: 84866423254     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.05.014     Document Type: Article

References (18)

1. McGoon MD, Kane GC. Pulmonary hypertension: diagnosis and management [published correction appears in Mayo Clin Proc. 2009;84(4):386]. Mayo Clin Proc. 2009;84(2):191-207.
2. McLaughlin VV, Archer SL, Badesch DB, et al ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc, and the Pulmonary Hypertension Association [published correction appears in Circulation. 2009; 120(2):e13]. Circulation. 2009;119(16):2250-2294.
3. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1, suppl):S55-S66.
4. Galiè N, Hoeper MM, Humbert M, et al ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) [published correction appears in Eur Heart J. 2011;32(8):926]. Eur Heart J. 2009;30(20):2493-2537.
5. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1, suppl):S78-S84.
6. Doran AK, Ivy DD, Barst RJ, Hill N, Murali S, Benza RL; Scientific Leadership Council of the Pulmonary Hypertension Association. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl. 2008(160):5-9. (Pubitemid 352000590)
7. Galiè N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med. 2003;2(2):123-137. (Pubitemid 37062722)
8. Oudiz RJ, Widlitz A, Beckmann XJ, et al. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest. 2004;126(1):90-94. (Pubitemid 38943122)
9. Yap RL, Mermel LA. Micrococcus infection in patients receiving epoprostenol by continuous infusion. Eur J Clin Microbiol Infect Dis. 2003;22(11):704-705. (Pubitemid 37491628)
10. Kallen AJ, Lederman E, Balaji A, et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol. 2008;29(4):342-349. (Pubitemid 351416985)
11. Centers for Disease Control and Prevention (CDC). Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension: seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep. 2007;56(8):170-172.
12. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376-387.
13. McGoon MD, Krichman A, Farber HW, et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008;83(8):923-931.
14. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164-172.
15. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13-22.
16. Ivy DD, Calderbank M, Wagner BD, et al. Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension. Infect Control Hosp Epidemiol. 2009; 30(9):823-829.
17. Rich JD, Glassner C, Wade M, et al. The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension. Chest. 2012;141(1): 36-42.
18. Akagi S, Matsubara H, Ogawa A, et al. Prevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertension. Circ J. 2007;71(4): 559-564. (Pubitemid 46513466)